Welcome to our dedicated page for Qualigen Therapeutics news (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics stock.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), now operating under the name AIxCrypto Holdings, Inc. with the ticker AIXC, generates news that spans both biotechnology and digital asset markets. Company press releases and SEC reports describe a transition from a clinical-stage oncology and infectious disease drug developer into a cross-disciplinary enterprise focused on decentralized AI, Web3 asset infrastructure, and intelligent trading systems.
News items for QLGN and AIXC include updates on strategic financings, such as the $41 million PIPE transaction led by Faraday Future Intelligent Electric Inc., which resulted in majority beneficial ownership and new governance arrangements. Coverage also highlights Nasdaq listing and compliance communications, including notices related to stockholder equity requirements and shareholder approval rules, and the company’s responses through private placements and stockholder meetings.
On the technology and crypto side, the company issues detailed announcements about the launch and evolution of its C10 Cryptocurrency Asset Treasury, which follows an 80% passive and 20% active allocation strategy to top cryptocurrencies, and about partnerships supporting this strategy, such as its agreement with BitGo for digital asset custody and liquidity access. Additional news focuses on the BesTrade DeAI Agent, C10 Index and treasury products, potential C10 ETF concepts, and ecosystem tokens like a potential C10 stablecoin and EAI + Crypto RWA dual-bridge products.
Biotech-focused updates continue to appear as well, including patent grants for QN-302 across numerous countries and descriptions of the company’s ongoing QN-302 clinical trial and Pan-RAS preclinical program. Governance and leadership changes, including new board appointments and executive roles associated with Faraday Future, are also recurring themes. Investors and observers can use this news stream to follow the company’s dual-track evolution in therapeutics and AI × Web3 initiatives.
Qualigen Therapeutics announces a $12 million registered direct offering with an institutional investor. This agreement includes the sale of 2,370,786 Common Shares, 1,000,000 Pre-Funded Warrants, and 1,348,314 Common Warrants at a price of $3.56 per share. The offerings are expected to close on December 18, 2020, pending customary conditions. The Common Warrants will have an exercise price of $4.07 and a two-year term. A.G.P./Alliance Global Partners is the sole placement agent for this offering.
Qualigen Therapeutics (Nasdaq: QLGN) announced a new patent for its ALAN technology, enhancing cancer treatment and imaging. This patent, issued by the U.S. Patent and Trademark Office, covers Anti-Nucleolin Agent-Conjugated Nanoparticles, which may improve radiation therapy and MRI imaging. The company holds exclusive rights to ALAN, which combines a DNA aptamer and gold nanoparticles for targeting tumor cells, with Phase 1 trials set for 2021. Qualigen's patent portfolio now includes 58 issued and pending patents, emphasizing its commitment to developing innovative cancer therapies.
Qualigen Therapeutics (Nasdaq: QLGN) announced the appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer, and Sidney Emery, Jr. as an independent director of the board, effective December 7, 2020. Broidrick, a biopharma executive with over 25 years of experience, will lead strategic initiatives focused on the therapeutics pipeline. Emery's addition increases the board's size to seven, enhancing its expertise. The management changes aim to advance the development of the company's lead compound AS1411 for COVID-19 and other cancer therapeutics.
Qualigen Therapeutics (Nasdaq: QLGN) has completed the recertification of its AS1411 supply, gearing up for Phase 2a efficacy trials aimed at treating COVID-19. The company plans to file for FDA approval and initiate trials in early 2021. AS1411, a nucleolin-targeting DNA aptamer, has shown promise in preclinical studies at the University of Louisville, indicating potential effectiveness against COVID-19 and other viruses. Qualigen holds exclusive U.S. patent rights for AS1411's use against COVID-19 and is progressing with IND-enabling studies.
Qualigen Therapeutics (Nasdaq: QLGN) reported significant advancements in its strategic plan in a letter from CEO Michael Poirier. The company is progressing with its lead drug AS1411, showing potent antiviral activity against SARS-CoV-2. A positive FDA response for AS1411's Pre-IND application paves the way for a Phase 2a trial in 2021. Despite a decrease in revenues to $0.8 million from $1.2 million year-over-year due to COVID-19, Qualigen raised $18 million in funding, ensuring sufficient capital to advance its clinical pipeline, including the COVID-19 antibody test.
Qualigen Therapeutics (Nasdaq: QLGN) has contracted with STA Pharmaceutical for GMP production of AS1411, its leading COVID-19 drug candidate, to facilitate upcoming clinical trials. Preclinical studies at the University of Louisville demonstrated AS1411's capability to protect cells from coronavirus damage. Qualigen aims to file an IND application in early 2021 and start Phase 2a clinical trials in COVID-19 patients by mid-2021. AS1411 has previously shown a strong safety profile in over 100 cancer patients.
Qualigen Therapeutics (Nasdaq: QLGN) received positive feedback from the FDA regarding its Type B Pre-IND meeting for AS1411, a nucleolin-targeting drug candidate aimed at treating COVID-19. The FDA supports moving forward with a Phase 2a proof-of-concept study, assessing safety and dosing in hospitalized patients. This progress allows Qualigen to prioritize AS1411's clinical trials starting in H1 2021, followed by studies on ALAN against acute myeloid leukemia. Past preclinical trials have shown AS1411's effectiveness against SARS-CoV-2, suggesting its potential as a novel antiviral therapeutic.
Qualigen Therapeutics (Nasdaq: QLGN) announced a partnership with Yi Xin Zhen Duan Jishu (Suzhou) Ltd to develop and sell advanced diagnostic test systems in China. This agreement includes cash payments in the hundreds of thousands, plus royalties on sales. Yi Xin gains exclusive rights for the Chinese market, allowing them to manufacture and sell both new and existing FastPack products. The CEO highlighted that this non-dilutive funding will support the company’s strategic shift towards therapeutic product development.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has expanded its research agreement with the University of Louisville to advance the development of its anticancer drug candidate AS1411-GNP, also known as ALAN. The amended agreement aims to conduct preclinical studies on acute myeloid leukemia (AML), glioblastoma, and non-small cell lung cancer. These studies are critical as they address significant unmet clinical needs in cancer treatment. Qualigen is targeting to initiate Phase 1 human trials for AML in 2021, which may expand its product pipeline significantly.
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) has filed a provisional patent application in partnership with the University of Louisville for a method to inhibit coronavirus infections using the antiviral candidate AS1411. This application aims to protect against SARS-CoV-2 via delivery mechanisms such as inhalers, nose sprays, or eye drops. The company plans to initiate IND-enabling studies and file for IND with the FDA in late 2020, with a goal to begin Phase 1/2 clinical trials in COVID-19 patients in early 2021.
FAQ
What is the current stock price of Qualigen Therapeutics (QLGN)?
What is the market cap of Qualigen Therapeutics (QLGN)?
